抗糖尿病药物的保护性质
Christian Gerdes1, Nicolle Müller1, Gunter Wolf1
1Department of Internal Medicine III, University Hospital Jena, D-07747 Jena, Germany.
Journal of clinical medicine
|May 27, 2023
概括
新型抗糖尿病药物,-葡萄糖共运输体2抑制剂 (SGLT2-I) 和类似葡萄糖的1受体激动剂 (GLP1-RA),在糖尿病中提供显著的保护. 这些药物减缓慢性病的进展,减少心血管疾病的风险.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内分泌学 在内分泌学.
- 心脏病学 心脏病学
背景情况:
- 慢性病 (CKD) 显著增加患病率和死亡率,特别是心血管 (CV) 原因,特别是糖尿病患者 (DM).
- 糖尿病本身会增加心血管风险,并加剧CKD的发展和进展.
- 在糖尿病患者中,有效的CKD管理,包括减缓其进展,与血糖控制一起至关重要.
研究的目的:
- 审查新型抗糖尿病药物的脏保护作用.
- 讨论-葡萄糖共运输体2抑制剂 (SGLT2-I) 和葡萄糖类1受体激活剂 (GLP1-RA) 在患有或没有DM的患者中治疗CKD的作用.
- 要突出目前使用这些药物的指导方针建议.
主要方法:
- 对心血管结局试验和临床指导方针的审查.
- 对SGLT2-I和GLP1-RA对结局的影响数据的分析.
- 讨论其他抗糖尿病药物的脏保护性质.
主要成果:
- GLP1-RA证明了大albuminuria风险的降低.
- SGLT2-I 显示了球透率 (GFR) 降低的风险降低,甚至在非糖尿病患者中也显示了好处.
- 对于患有DM,CKD和/或心血管风险增加的患者,建议使用SGLT2-I和GLP1-RA.
结论:
- 新型抗糖尿病药物SGLT2-I和GLP1-RA,除了降低葡萄糖,还提供了显著的脏保护.
- 这些药物对于控制糖尿病患者的CKD进展和心血管风险至关重要.
- 该审查还考虑了其他抗糖尿病药物的脏保护方面.
关键词:
作为GLP1受体的激动剂.SGLT2 抑制剂的使用.专辑蛋白尿症是什么意思抗糖尿病药物 抗糖尿病药物慢性脏疾病 慢性脏疾病在糖尿病中,糖尿病是血糖性糖尿病.美国GFRGFR神经保护神经保护治疗治疗治疗治疗治疗治疗更多相关视频
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
614
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
489
相关概念视频
01:16Antihypertensive Drugs: Action of Diuretics
823
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
823
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
41
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
41
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
660
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
660
01:22Heart Failure Drugs: Diuretics
430
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
430
01:15Antihypertensive Drugs: Thiazide-Class Diuretics
774
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
774
01:22Drug Elimination by Renal Route: Tubular Reabsorption
3.5K
During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. However, the majority of drugs are either weak acids or weak bases, and their ionization level is dependent on pH. By altering the pH of urine, the...
3.5K